2012


To access this material please log in or register

Register Authorize
2012/№5

Angiotensin II antagonists: “pro” stand

Koziolova N. А.

Keywords: AII receptor antagonists, ACE inhibitors, treatment, cardiovascular diseases

DOI: 10.18087 / rhj.2012.5.1749

Editorial board opinion. During discussion by the editorial board of the article by S. V. Stolov “Effective inactivation of of the renin-angiotensin-aldosterone system. Choosing a drug class?” relevance of the discussed problem was noted. However, not all associate editors agreed with some conclusions of the author. In the following commentary, a common opinion of the editorial board, concerning the problem studied in the article by S. V. Stolov, is given.
  1. Мареев В. Ю. Антагонисты рецепторов к ангиотензину II в клинической практике в начале XXI века. Яркий свет в конце длинного тоннеля. Consilium medicum. 2001;3 (2):73–78.
  2. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345 (12):851–860.
  3. Berl T, Hunsicker LG, Lewis JB et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med. 2003;138 (7):542–549.
  4. Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21 (5):875–886.
  5. Papademetriou V, Farsang C, Elmfeldt D et al. Stroke prevention with the angiotensin II type 1‑receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol. 2004;44 (6):1175–1180.
  6. Zanchetti A, Elmfeldt D. Findings and implications of the Study on COgnition and Prognosis in the Elderly (SCOPE) – a review. Blood Press. 2006;15 (2):71–79.
  7. ALLHAT Officers and Coordinators for the ALLHAT Colla­borative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288 (23):2981–2997.
  8. Pitt B, O'Neill B, Feldman R et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol. 2001;87 (9):1058–1063.
  9. Rouleau JL, Warnica WJ, Baillot R et al. Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery. Circulation. 2008;117 (1):24–31.
  10. Braunwald E, Domanski M J, Fowler S E., for the PEACE Trial investigators et al. Angiotensin converting enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351 (20):2058–2068.
  11. Ferrari R; Perindopril and Remodeling in Elderly with Acute Myocardial Infarction Investigators. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remo­deling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med. 2006;166 (6):659–666.
  12. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358 (9287):1033–1041.
  13. Marre M, Lievre M, Chatellier G et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ. 2004;328 (7438):495.
  14. Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353 (9153):611–616.
  15. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ. 1998;317 (7160):713–720.
  16. Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ. 2004;329 (7477):1248–1249.
  17. McMurray J. Angiotensin receptor blockers and myocardial infarction: analysis of evidence is incomplete and inaccurate. BMJ. 2005; 330 (7502):1269; author reply 1270–1271.
  18. Tsuyuki T, McDonald MA. Angiotensin receptor blockers do not increase risk of myocardial infarction. Circulation 2006;114 (8):855–860.
  19. Opie LH. Angiotensin receptor blockers and myocardial infarction: direct comparative studies are needed. BMJ. 2005;330 (7502):1270–1271.
  20. Lewis EJ. Angiotensin receptor blockers and myocardial infarction: results reflect different cardiovascular states in patients with types 1 and 2 diabetes. BMJ. 2005;330 (7502):1269–1270.
  21. Yousef ZR, Leyva F, Gibbs C. Angiotensin receptor blockers and myocardial infarction: cautions voiced are biologically credible. BMJ. 2005; 330 (7502):1269; author reply 1270–1271.
  22. Levy BI. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the rennin-angiotensin system. Circulation. 2004;109 (1):8–13.
  23. Zhu L, Carretero OA, Xu J et al. Angiotensin II type 2 receptor-stimulated activation of plasma prekallikrein and bradykinin release: role of SHP-1. Am J Physiol Heart Circ Physiol. 2012 Jun 15;302 (12):H2553–2559.
  24. Xu J, Carretero OA, Shesely EG et al. The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice. Exp Physiol. 2009;94 (3):322–329.
  25. Lee S, Brait VH, Arumugam TV et al. Neuroprotective effect of an angiotensin receptor type 2 agonist following cerebral ische­mia in vitro and in vivo. Exp Transl Stroke Med. 2012;4 (1):16.
  26. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation. 2006;114 (8):838–854.
  27. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362 (9395):1527–1535.
  28. Reboldi G, Angeli F, Cavallini C et al. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens. 2008 Jul;26 (7):1282–1289.
  29. Verdecchia P, Angeli F, Gattobigio R, Reboldi GP. Do angiotensin II receptor blockers increase the risk of myocardial infarction? Eur Heart J. 2005;26 (22):2381–2386.
  30. McDonald MA, Simpson SH, Ezekowitz JA et al. Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ. 2005;331 (7521):873.
  31. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338: b1665.
  32. Volpe M, Mancia G, Trimarco B. Angiotensin II receptor blo­ckers and myocardial infarction: deeds and misdeeds. J Hypertens. 2005;23 (12):2113–2118.
  33. Baker WL, Coleman CI, Kluger J et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease.Ann Intern Med. 2009;151 (12):861–871.
  34. Matchar DB, McCrory DC, Orlando LA et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibi­tors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008;148 (1):16–29.
  35. Messerli FH, Bangalore S, Ruschitzka F. Angiotensin receptor blockers: baseline therapy in hypertension? Eur Heart J. 2009;30 (20):2427–2430.
  36. Al Khalaf MM, Thalib L, Doi SA. Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2009;9 (1):29–43.
  37. Cheung BM, Cheung GT, Lauder IJ et al. Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension. J Hum Hypertens. 2006;20 (1):37–43.
  38. Walker E, Hernandez AV, Kattan MW. Meta-analysis: Its strengths and limitations. Cleve Clin J Med. 2008;75 (6):431–439.
  39. Bangalore S, Kumar S, Wetterslev J, Messerli FH. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ. 2011;342: d2234. doi: 10.1136 / bmj.d2234.
  40. Fretheim A, Odgaard-Jensen J, Brørs O et al. Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis. BMC Med. 2012;10:33.
  41. Yusuf S, Teo K, Anderson C et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372 (9644):1174–1183.
  42. Yusuf S, Diener HC, Sacco RL et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359 (12):1225–1237.
  43. Van Mieghem W, Billiouw JM, Brohet C et al. Are ACE-inhibitors or ARB's still needed for cardiovascular prevention in high risk patients? Insights from profess and transcend. Acta Clin Belg. 2010;65 (2):107–114.
  44. McMurray JJ, Holman RR, Haffner SM et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362 (16):1477–1490.
  45. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345 (12):861–869.
  46. Massie BM, Carson PE, McMurray JJ et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359 (23):2456–2467.
  47. Pfeffer MA, Swedberg K, Granger CB et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbi­dity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362 (9386):759–766.
  48. Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362 (9386):772–776.
  49. McMurray JJV, Ostergren J, Swedberg K et al; for the CHARM investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362 (9386):767–771.
  50. Young JB, Dunlap ME, Pfeffer MA et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation. 2004;110 (17):2618–2626.
  51. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left – ventricular ejection fraction: the CHARM Preserved Trial. Lancet. 2003;362 (9386):777–781.
  52. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345 (23):1667–1675.
  53. Heran BS, Musini VM, Bassett K et al. Angiotensin receptor blockers for heart failure. Cochrane Database Syst Rev. 2012;4: CD003040.
  54. Suzuki H, Kanno Y. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. Hypertens Res. 2005;28 (4):307–14.
  55. Dahlof B, Devereux R, Kjeldsen S et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359 (9311):995–1003.
  56. Sawada T, Yamada H, Dahlöf B, Matsubara H. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J. 2009;30 (20):2461–2469.
  57. Mochizuki S, Dahlof B, Shimizu M et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet. 2007;369 (9571):1431–1439.
  58. Ogihara T, Fujimoto A, Nakao K, Saruta T. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Expert Rev Cardiovasc Ther. 2008;6 (9):1195–1201.
  59. Kasanuki H, Hagiwara N, Hosoda S et al. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J. 2009;30 (10):1203–1212.
  60. Schrader J, Luders S, Kulschewski A et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36 (6):1218–1226.
  61. Imai E, Chan JC, Ito S et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia. 2011;54 (12):2978–2986.
  62. Berl T, Hunsicker LG, Lewis JB et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med. 2003;138 (7):542–549.
  63. Suzuki H, Kanno Y, Sugahara S et al. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis. 2008;52 (3):501–506.
  64. Yusuf S, Teo KK, Pogue J et al. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358 (15):1547–1559.
  65. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342 (3):145–153.
  66. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349 (9054):747–752.
  67. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355 (9215):1582–1587.
  68. Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360 (9335):752–760.
  69. Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349 (20):1893–1906.
  70. McMurray J, Solomon S, Pieper K et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol. 2006;47 (4):726–733.
  71. Singh A, Bangalore S. Do angiotensin receptor blockers prevent myocardial infarctions as well as other initial therapies? Curr Opin Cardiol. 2012;27 (4):381–385.
  72. Kanehira T, Tani T, Takagi T et al. Angiotensin II type 2 receptor gene deficiency attenuates susceptibility to tobacco-specific nitrosamine-induced lung tumorigenesis: involvement of transforming growth factor-b-dependent cell growth attenuation. Cancer Res. 2005;65 (17):7660–7665.
  73. Clere N, Corre I, Faure S et al. Def iciency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis. Int J Cancer. 2010;127 (10):2279–2291.
  74. Sipahi I, Debanne SM, Rowland DY et al. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11 (7):627–636.
  75. Meredith PA, McInnes GT. Angiotensin-receptor blockade, cancer, and concerns. Lancet Oncol. 2010;11 (9):819.
  76. Siragy HM. Comparing angiotensin II receptor blockers on bene­fits beyond blood pressure. Adv Ther. 2010;27 (5):257–284.
  77. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363 (9426):2022–2031.
  78. Bangalore S, Kumar S, Kjeldsen SE et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analy­ses of 324,168 participants from randomised trials. Lancet Oncol. 2011;12 (1):65–82.
  79. The ARB Trialists Collaboration Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals. J Hypertens. 2011;29 (4):623–635.
  80. Huang CC, Chan WL, Chen YC et al. Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension. Am J Cardiol. 2011;107 (7):1028–1033.
  81. FDA Drug Safety Communication Ongoing safety review of the angiotensin receptor blockers and cancer. 2010. Available at: http://www.fda.gov / Drugs / DrugSafety / PostmarketDrugSafety­Information-forPatientsandProviders / ucm218845.htm. Accessed March 2011.
  82. Sugiura R, Ogawa H, Oka T et al. Candesartan-based therapy and risk of cancer in patients with systemic hypertension (Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] substudy). Am J Cardiol. 2012;109 (4):576–580.
  83. Furie KL, Kasner SE, Adams RJ et al. American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association / american stroke association. Stroke. 2011;42 (1):227–276.
  84. Daskalopoulou SS, Khan NA, Quinn RR et al. The 2012 Canadian hypertension education program recommendations for the mana­gement of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Stroke. 2012;43 (1):113–1139.
  85. McManus RJ, Caulfield M, Williams B; National Institute for Health and Clinical Excellence. NICE hypertension guideline 2011: evidence based evolution. BMJ. 2012;344: e181. doi: 10.1136 / bmj.e181.
  86. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25 (6):1105–1187.
  87. Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27 (11):2121–2158.
  88. Chobanian AN, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA. 2003;289 (19):2560–2572.
  89. Российское медицинское общество по артериальной гипертонии (РМОАГ), Всероссийское научное общество кардиологов (ВНОК). Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). 2010 г. Доступно на: http://gipertonik.ru / files / recommendation-ag-2010.pdf
  90. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. The Dutch TIA Trial Study Group. Stroke. 1993;24 (4):543–548.
  91. Barer DH, Cruickshank JM, Ebrahim SB, Mitchell JR. Low dose beta blockade in acute stroke («BEST» trial): an evaluation. Br Med J (Clin Res Ed). 1988;296 (6624):737–741.
  92. Post-stroke antihypertensive treatment study. A preliminary result. PATS Collaborating Group. Chin Med J (Engl). 1995;108 (9):710–717.
  93. Bosch JJ, Yusuf S, Pogue J et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ. 2002;324 (7339):699–702.
  94. Staessen JA, Thijs L, Celis H et al. Dihydropyridine calcium-channel blockers for antihypertensive treatment in older patients – evidence from the Systolic Hypertension in Europe Trial. S Afr Med J. 2001;91 (12):1060–1068.
  95. Diener HC. Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs. J Hypertens Suppl. 2009;27 (5):S31‑S36.
  96. Lee M, Saver JL, Hong KS et al. Renin-Angiotensin system modulators modestly reduce vascular risk in persons with prior stroke. Stroke. 2012;43 (1):113–119.
  97. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention.Europace. 2011;13 (3):308–328.
  98. Wachtell K, Lehto M, Gerdts E et al. Angiotensin-II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45 (5):712–719.
  99. Schmieder RE, Kjeldsen SE, Julius S et al. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blo­ckade: the VALUE trial. J Hypertens. 2008;26 (3):403–411.
  100. Hansson L, Lindholm LH, Ekbom T et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354 (9192):1751–1756.
  101. Haywood LJ, Ford CE, Crow RS et al. ALLHAT Collaborative Research Group. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol. 2009;54 (22):2023–2031.
  102. Salehian O, Healey J, Stambler B et al. HOPE Investigators. Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study. Am Heart J. 2007;154 (3):448–453.
  103. Healey JS, Baranchuk A, Crystal E et al. Prevention of atrial fibrillation with angiotensin – converting enzyme inhibitors and angiotensin receptor blockers: a meta – analysis. J Am Coll Cardiol. 2005;45 (11):1832–1839
  104. Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J. 2006;152 (2):217–222.
  105. Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis. Am J Ther. 2008;15 (1):36–43.
  106. Schneider MP, Hua TA, Böhm M et al. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol. 2010;55 (21):2299–2307.
  107. Tveit A, Grundvold I, Olufsen M et al. Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol. 2007;120 (1):85–91.
  108. Palardy M, Ducharme A, Nattel S et al. Absence of protective effect of renin-angiotensin system inhibitors on atrial fibrillation deve­lopment: insights from the Canadian Trial of Atrial Fibrillation (CTAF). Can J Cardiol. 2008;24 (9):709–713.
  109. Disertori M, Latini R, Barlera S et al. GISSI-AF Investigators. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360 (16):1606–1617.
  110. Dabrowski R, Borowiec A, Smolis-Bak E et al. Effect of combined spironolactone-β-blocker ± enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study). Am J Cardiol. 2010;106 (11):1609–1614.
  111. Yusuf S, Healey JS, Pogue J et al. ACTIVE I Investigators. Irbesartan in patients with atrial fibrillation. N Engl J Med. 2011;364 (10):928–938.
  112. Yamashita T, Inoue H, Okumura K et al. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace. 2011;13 (4):473–479.
  113. Goette A, Schön N, Kirchhof P et al. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol. 2012;5 (1):43–51.
  114. Pedersen OD, Bagger H, Kober L et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 1999;100 (4):376–380.
  115. Vermes E, Tardif JC, Bourassa MG, Racine N et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation. 2003;107 (23):2926–2931.
  116. Maggioni AP, Latini R, Carson PE et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2005;149 (3):548–557.
  117. DucharmeA, SwedbergK, PfefferMA et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J. 2006;152 (1):86–92.
  118. Massie BM, Carson PE, McMurray JJ et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359 (23):2456–2467.
  119. Murray KT, Rottman JN, Arbogast PG et al. Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. Heart Rhythm. 2004;1 (6):669–675.
  120. Ueng KC, Tsai TP, Yu WC et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation: results of a prospective and controlled study. Eur Heart J 2003;24:2090–2098.
  121. Fazio G, Pizzuto C, Sutera L, et al. Inefficiency of renin-angiotensin inhibitors in preventing atrial fibrillation in patients with a normal heart. Minerva Cardioangiol. 2007;55 (3):311–315.
  122. Madrid AH, Marin IM, Cervantes CE et al. Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers. J Renin Angiotensin Aldosterone Syst. 2004;5 (3):114–120.
  123. Fogari R, Derosa G, Ferrari I et al. Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. Am J Hypertens. 2008;21 (9):1034–1039.
  124. Study to Determine the Efficacy of Perindopril to Prevent the Recur­rence of Atrial Fibrillation in Patients With Essential Hypertension (CTAF‑2). Available on: http://clinical­trials.gov / show / NCT00461903.
  125. The Use of DIOVAN to Reduce Post-Cardioversion Recurrence of Atrial Fibrillation Trial (the DRAFT Trial). Available on: http://clinicaltrials.gov / show / NCT00343499.
  126. Goette A, D'Alessandro A, Bukowska A et al. Rationale for and design of the CREATIVE-AF trial: randomized, double-blind, placebo-controlled, crossover study of the effect of irbesartan on oxidative stress and adhesion molecules in patients with persistent atrial fibrillation. Clin Drug Investig. 2008;28 (9):565–572.
  127. EPLERAF-Study: Eplerenone in the Prevention of Atrial Fibrillation Recurrences After Cardioversion. Available on: http://clinicaltrials.gov / show / NCT00647192.
  128. Routine Versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure (RACE 3). Available on: http://clinicaltrials.gov / show / NCT00877643.
  129. Spironolactone for Paroxysmal Atrial Fibrillation. Available on: http://clinicaltrials.gov / show / NCT00689598.
  130. Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter (PREFACE). Available on: http://clinicaltrials.gov / show / NCT00736294.
  131. The Effect of Losartan on Atrial Fibrillation (AF) Burden and Pacemaker Dependence in Patients With Sick Sinus Syndrome. Available on: http://clinicaltrials.gov / show / NCT00647257.
  132. Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation. Available on: http://clinicaltrials.gov / show / NCT00141778.
  133. PREvention of Atrial Fibrillation in patientS Undergoing thorAcic surGEry for Lung Cancer (PRESAGE). Available on: http://clinicaltrials.gov / show / NCT01281787.
  134. Dragomir A, Côté R, Roy L et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care. 2010;48 (5):418–425.
  135. Kronish IM, Woodward M, Sergie Z et al. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation. 2011;123 (15):1611–1621.
  136. Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff (Millwood). 2011;30 (1):91–99.
  137. Morimoto T, Gandhi TK, Fiskio JM et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract. 2004;10 (4):499–509.
  138. Bangalore S, Kumar S, Messerli FH. Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians’ Desk Reference. Am J Med. 2010;123 (11):1016–1030.
  139. Matchar DB, McCrory DC, Orlando LA et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhi­bitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008;148 (1):16–29.
Koziolova N. А. Angiotensin II antagonists: “pro” stand. Russian Heart Journal. 2012;11(5):285-302.

To access this material please log in or register

Register Authorize
Ru En